Assessment cycle 2026 Q3 — page 9
Documents ratified in the 2026 Q3 assessment cycle, which ran from 1 July 2026 to 30 September 2026 and was ratified on 18 September 2026.
Documents ratified
-
Permission from a competent authority to place a medicine on the market for a stated indication. Specific to product, indication, presentation and jurisdiction.
30 Jul 2026 -
Holding no marketing authorisation for the use in question. A compound may be approved in one indication and unapproved in another, and approved in one jurisdiction and…
30 Jul 2026 -
Use of an authorised product outside the terms of its authorisation. A regulated product used outside its licence, and distinct from an unapproved product, though the…
30 Jul 2026 -
The most prominent warning a competent authority can require in product information. Signals regulatory concern; does not itself establish that the risk is realised in…
30 Jul 2026 -
The collection and analysis of reports of suspected adverse reactions after authorisation. Establishes that an event has been reported and, for an event named in a…
30 Jul 2026 -
Increased reporting of an adverse event following publicity about it, which inflates a pharmacovigilance signal without any change in incidence.
30 Jul 2026 -
The Anatomical Therapeutic Chemical classification assigned by the World Health Organization. Assigned to authorised substances; its absence indicates that no…
30 Jul 2026 -
A unique identifier assigned to a chemical substance by the Chemical Abstracts Service. An identifier and not a statement of legal or quality status.
30 Jul 2026 -
A preparation made by a pharmacy for an individual patient. Subject to a different regulatory framework from a manufactured medicine, and not equivalent to an authorised…
30 Jul 2026 -
The quarterly period in which the Institute ratifies documents. Every document carries the cycle in which its current version was ratified.
30 Jul 2026 -
Approval of a document by the assessment committee following external review and, where applicable, the disposition of a public comment period. A document is published…
30 Jul 2026 -
A defined window during which formal submissions may be made on a draft. Every submission is signed, carries a declared interest, receives a secretariat response and is…
30 Jul 2026 -
The Institute’s recorded decision on a submission: accepted, accepted in part, noted without amendment, or not accepted with a stated reason. Submissions that are not…
30 Jul 2026 -
A financial or non-financial relationship disclosed by a person contributing to an Institute document or submitting to a comment period. A declaration is not a…
30 Jul 2026 -
An Institute-constructed trial record representing an instalment, sub-study or regional extension of a real development programme, published to carry a methodological…
30 Jul 2026 -
A marker applied to any figure, worked example or value the Institute has constructed for teaching purposes rather than extracted from a source. The boundary between…
30 Jul 2026 -
The cycle in which a document is scheduled for re-examination. A document past its next-review date without a new version is flagged in the registry.
30 Jul 2026 -
The edition of a document. Any change to a number, a rating or a conclusion increments the version; superseded versions remain published, marked and linked from the…
30 Jul 2026 -
The record of every correction made to a published document, including corrections that do not change a conclusion. Published in full so that a reader can judge which…
30 Jul 2026 -
The record of third-party data submitted to the Institute, what was submitted, by whom, and whether it was used. Data submitted and not used are recorded with the reason.
30 Jul 2026 -
The stable reference for an Institute document, of the form CEI-XX-nnn. A document that changes type retains its original identifier so that citations to it remain…
30 Jul 2026 -
Atherosclerotic obstruction of the lower-limb arteries producing exertional ischaemic symptoms, with objective confirmation by ankle–brachial index or imaging.
06 Aug 2026 -
Interventions proposed to modify rate of biological ageing, assessed by composite biomarker clocks, functional measures, or mortality.
25 Jul 2026 -
Amylin analogue, short-acting. Pramlintide reproduces the postprandial actions of endogenous amylin, which is deficient in insulin-deficient diabetes: it slows gastric emptying…
Moderate15 Jul 2026 -
Endogenous pyridine dinucleotide coenzyme. NAD+ is the central redox coenzyme of intermediary metabolism and the substrate of the sirtuin and poly-ADP-ribose polymerase enzyme families. Tissue…
Very low23 Aug 2026 -
Determination of aggregate content by size-exclusion chromatography
High26 Aug 2026 -
Chair, Board of Trustees. Emeritus Professor of Clinical Pharmacology, Uppsala
30 Jul 2026 -
Deputy Chair, Board of Trustees. Consultant in Public Health Medicine
30 Jul 2026 -
Trustee, Chair of the Audit and Conflicts Committee. Former Chair, national research-integrity panel
30 Jul 2026 -
Trustee, Chair of the Analytical Standards Committee. Independent consultant; formerly Head of Analytical Development, contract manufacturing sector
30 Jul 2026 -
Trustee. Associate Professor of Pharmacy Practice
30 Jul 2026 -
Trustee. Professor of Hepatology
30 Jul 2026 -
Trustee, Honorary Treasurer. Chartered accountant; charity finance sector
30 Jul 2026 -
Trustee, Patient and Public Involvement lead. Consultant Physician in Metabolic Medicine
30 Jul 2026 -
Chair, Assessment Committee. Professor of Diabetes and Endocrinology
30 Jul 2026 -
Deputy Chair, Assessment Committee. Consultant Cardiologist; Reader in Cardiovascular Medicine
30 Jul 2026 -
Lead Statistician, Assessment Committee. Senior Statistician, independent
30 Jul 2026 -
Assessment Committee member, clinical pharmacology. Clinical Pharmacologist, teaching hospital
30 Jul 2026 -
Assessment Committee member, safety. Consultant in Pharmacovigilance
30 Jul 2026 -
Assessment Committee member, chemistry. Professor of Medicinal Chemistry
30 Jul 2026
page 9 of 14